| scholarly article | Q13442814 |
| P50 | author | Maarten Limper | Q99352054 |
| Cecilia Nalli | Q114416234 | ||
| Andrea Doria | Q38544117 | ||
| Pier Luigi Meroni | Q38544871 | ||
| Carlo Alberto Scirè | Q45900686 | ||
| Nathalie Costedoat-Chalumeau | Q47262464 | ||
| Ricard Cervera i Segura | Q53547424 | ||
| Maria G Tektonidou | Q57034988 | ||
| Éric Hachulla | Q57413861 | ||
| Véronique Ramoni | Q64015141 | ||
| Zahir Amoura | Q69662859 | ||
| Angela Tincani | Q73304219 | ||
| Stefano Bombardieri | Q73477457 | ||
| Maurizio Cutolo | Q79075844 | ||
| Marta Mosca | Q90560735 | ||
| Tadej Avčin | Q91528571 | ||
| P2093 | author name string | Luc Mouthon | |
| Thomas Dörner | |||
| Jacob M van Laar | |||
| João Eurico Fonseca | |||
| David Launay | |||
| Ana Vieira | |||
| Rosaria Talarico | |||
| Matthias Schneider | |||
| Gerd Burmester | |||
| Linda Carli | |||
| Vanessa Smith | |||
| Carlo Maurizio Montecucco | |||
| Carla Macieira | |||
| Maria Francisca Moraes-Fontes | |||
| Martina Basile | |||
| Filipa Lourenco | |||
| Ilaria Galetti | |||
| P2860 | cites work | Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines | Q22255576 |
| VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24632982 | ||
| Prophylaxis of the antiphospholipid syndrome: a consensus report | Q28196923 | ||
| Evidence based treatment of the antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis | Q28210747 | ||
| Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals | Q28217805 | ||
| Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab | Q28260452 | ||
| The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study | Q30885847 | ||
| EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics | Q33284736 | ||
| A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome | Q33404206 | ||
| Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. | Q33419171 | ||
| The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features | Q33420116 | ||
| Current treatment of antiphospholipid syndrome: lights and shadows | Q33423959 | ||
| EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome | Q33731711 | ||
| EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs | Q34132211 | ||
| 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends | Q34400373 | ||
| Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis | Q35189289 | ||
| Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy | Q37137892 | ||
| International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies | Q37939730 | ||
| Guidelines on the investigation and management of antiphospholipid syndrome | Q37982121 | ||
| Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. | Q38159868 | ||
| 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome | Q38197819 | ||
| 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends | Q38211487 | ||
| European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. | Q39284670 | ||
| Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome | Q39608521 | ||
| Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study | Q40188551 | ||
| Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy | Q44585678 | ||
| Repeated low-dose courses of rituximab in SLE-associated antiphospholipid syndrome: Data from a tertiary dedicated centre. | Q44764615 | ||
| Closing the Serological Gap in the Antiphospholipid Syndrome: The Value of "Non-criteria" Antiphospholipid Antibodies | Q46988388 | ||
| Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. | Q47680027 | ||
| Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study. | Q50907696 | ||
| Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. | Q53190445 | ||
| Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. | Q53521432 | ||
| McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome | Q57307370 | ||
| Pregnancy loss: French clinical practice guidelines | Q59291288 | ||
| Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies | Q83389363 | ||
| First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss | Q83992557 | ||
| Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk | Q86646346 | ||
| Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use | Q88458190 | ||
| The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review | Q88741390 | ||
| Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome | Q90007363 | ||
| P433 | issue | Suppl 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antiphospholipid syndrome | Q582207 |
| P304 | page(s) | e000785 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | RMD open | Q27726913 |
| P1476 | title | Antiphospholipid syndrome: state of the art on clinical practice guidelines | |
| P478 | volume | 4 |
Search more.